ClinicalTrials.gg
CompletedNCT06245538ExStressUpdated Dec 2, 2025

Exercise Intensity on Brain & Mental Health in Stress

An interventional study of Seated rest and Exercise at moderate intensity in Healthy Adults and Adults With Stress-related Symptoms, sponsored by The Swedish School of Sport and Health Sciences. Completed at 1 site in Sweden. Open to participants aged 20 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-02.

Primary conditionNeuroinflammatory Diseases(the registry's first term)UnverifiedIs this wrong?Neuroinflammatory Diseases is a broad heading, used only when no more specific condition is named. No better condition is named, so the registry's term is kept.

Sponsored by The Swedish School of Sport and Health Sciences · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
20 Years to 40 Years
Sex
All
01

Study summary

This study aims to examine the role of exercise intensity in the acute effects of a single bout of aerobic exercise on neurotrophic factors, biomarkers of stress and inflammation, working memory task-related changes in prefrontal cortex oxygenation in adults with sub-clinical levels of stress-related symptoms.

Read the detailed description

This study initially set out to include 43 adult (20 - 40 years) participants experiencing stress-related symptoms and 43 healthy controls, matched by age, sex, and fitness. These procedures were approved by the Swedish Ethical Review Autority (Approval number 2022-07297-01 and 2023-08181-02). Due to recruitment difficulties the design was later changed to include all individuals with sub-clinical stress symptoms and using stress as a covariate instead of comparing groups of healthy and stressed individuals (Ethical review approval number 2025-01786-02). This is a randomized-order crossover experimental trial with three experimental conditions separated by a wash-out period of 7 days: 20-min leg cycling exercise at moderate intensity, 20-min leg cycling exercise at vigorous intensity, and 20-min seated rest (passive control condition).

Prior to entering the study, study inclusion/exclusion criteria will be controlled using digital screening. Before the experimental sessions, all participants will complete two introductory study visits. At the first introductory visit, the participant's maximal oxygen uptake (VO2max) will be determined using a fitness test. This information will be used to determine the individual workloads (% of individual VO2max) that the participant will be cycling at during the experimental session. At the second introductory visit, participants will complete a familiarization session, in which key methodological aspects of the study will be introduced to participants. Participants' augmentation index, as a measure of arterial stiffness, will also be completed during this visit.

In each of the three experimental sessions, participants will perform a computerized working memory task (n-back task) pre- and post-exercise (or seated rest). During the working memory task, functional near-infrared spectroscopy (fNIRS) will be used to measure task-related changes in prefrontal cortex oxygenation. As such, each participant will complete six fNIRS measurements, two measurements (pre, post) for each of the three experimental sessions (moderate, high, control). Simultaneous with the fNIRS measurements, blood flow velocity in the left and right middle cerebral artery will be assessed during the n-back tasks using Transcranial Doppler ultrasound. At each experimental session, blood will also be sampled from the antecubital vein at six time points: pre the first n-back task, pre and post the cycling exercise (or seated rest), pre and post the second n-back task, and post the final 10-min seated rest. Whole blood samples will be assessed for blood gases, acid-base status, electrolytes, hematocrit level, platelet count, and glucose. The separated blood plasma and serum samples will be used for measurements of neurotrophic factors, lactate, biomarkers of stress and inflammation, and factors involved in blood glucose control. Blood samples will also be used for targeted DNA screening for alleles of the BDNF.

Additionally, the participant's current mood, mental and physical fatigue, heart rate variability (HRV) and blood pressure will be assessed during four 10-min seated rest periods: pre and post n-back, and pre and post cycling exercise (or seated rest). Prior to each experimental study session, participants will have assessments of sleep quality the night before, current health status, physical activity level during the week prior to the test day, sleepiness level the last 10 min, and current mood. Participant's sleep quality and heart rate variability during the night before and after each experimental session will also be assessed.

A release of an updated version of this study was attempted prior to completion of the study on October 3 2025, but due to a shutdown of the US goverment this was not possible to register until in November 24 2025.

02

Conditions studied

  • Healthy Adults
  • Adults With Stress-related Symptoms

Browse trials for

Keywords

  • FNIRS
  • Neuroplasticity
  • Neuroinflammation
  • cerebral blood flow
  • Exercise intensity
  • Psychological stress
03

In context

Neuroinflammatory Diseases Unverified

180 studies on the registry are indexed under Neuroinflammatory Diseases; 81 are open to participants now.

This study's enrollment of 24 is below the median of 44 across 113 interventional studies indexed under Neuroinflammatory Diseases.

Browse Neuroinflammatory Diseases studies →

Lead sponsor

The Swedish School of Sport and Health Sciences is the lead sponsor of 12 studies on the registry; 5 are open to participants now.

Compared within Neuroinflammatory Diseases, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants experiencing sub-clinical levels of stress-related symptoms:

  • Age: 20-40 years
  • Absence of to physical exercise
  • Do not participate in any other study
  • Total score on the self-assessment scale 4-factor Shirom-Melamed Burnout Measure-19 lower than or equal to 4.00

Exclusion criteria

Exclusion Criteria:

  • Medical to catheterization of the antecubital vein and blood sampling
  • Dementia
  • Alcohol abuse
  • Smoking
  • Chronic medication that is considered to affect study outcomes
  • Chronic disease/syndrome such as migraine, fibromyalgia, chronic fatigue syndrome, bipolar syndrome, high blood pressure, cardiovascular disease, (COPD) or other lung disease
  • Post-COVID
  • Other somatic diseases, disorders, or injuries that may affect the physical ability during physical exercise
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Seated rest

    Participants will be resting while seated on a comfortable chair for 20 minutes

    Behavioral: Seated rest

  • Experimental
    Exercise at moderate intensity

    Participants will perform a 20-min leg cycling exercise on a cycle ergometer at moderate intensity (60% of VO2max)

    Behavioral: Exercise at moderate intensity

  • Experimental
    Exercise at vigorous intensity

    Participants will perform a 20-min leg cycling exercise on a cycle ergometer at vigorous intensity (80% of VO2max)

    Behavioral: Exercise at vigorous intensity

Interventions

  • BehavioralSeated rest

    Participants will be resting while seated on a comfortable chair for 20 minutes

  • BehavioralExercise at moderate intensity

    Participants will perform a 20-min leg cycling exercise on a cycle ergometer at moderate intensity (60% of VO2max)

  • BehavioralExercise at vigorous intensity

    Participants will perform a 20-min leg cycling exercise on a cycle ergometer at vigorous intensity (80% of VO2max)

06

What researchers measure

Primary outcomes

  1. Changes in cerebral blood flow in prefrontal cortex

    working memory task-related changes in prefrontal cortex oxygenation measured using functional near-infrared spectroscopy

    Time frame: from before to after 20 minutes of exercise or seated rest

Secondary outcomes

  1. Brain-derived neurotrophic factor

    pro and mature BDNF in blood sample taken from the forearm antecubital vein; concentrations measured in blood plasma and serum

    Time frame: At three time points before and four time points after 20 minutes of exercise or seated rest (In total over 2 hours)

  2. Working memory performance

    computerized working memory task (n-back: 1-, 2- and 3-back)

    Time frame: At one time point before and one time point after 20 minutes of exercise or seated rest (In total over 1 hour)

  3. DNA allele of brain-derived neurotrophic factor

    in blood sample taken before intervention from the forearm antecubital vein

    Time frame: At one time point at baseline

  4. Platelet count

    in blood sample taken from the forearm antecubital vein

    Time frame: At three time points before and four time points after 20 minutes of exercise or seated rest (In total over 2 hours)

  5. Cortisol

    biomarker of stress; in blood sample taken from the forearm antecubital vein

    Time frame: At three time points before and four time points after 20 minutes of exercise or seated rest (In total over 2 hours)

  6. Epinephrine

    biomarker of stress; in blood sample taken from the forearm antecubital vein

    Time frame: At three time points before and four time points after 20 minutes of exercise or seated rest (In total over 2 hours)

  7. Norepinephrine

    biomarker of stress; in blood sample taken from the forearm antecubital vein

    Time frame: At three time points before and four time points after 20 minutes of exercise or seated rest (In total over 2 hours)

  8. C-reactive protein (CRP)

    as a measure of systemic inflammation; in blood sample taken from the forearm antecubital vein

    Time frame: At three time points before and four time points after 20 minutes of exercise or seated rest (In total over 2 hours)

  9. Interleukin 6 (IL-6)

    as a measure of systemic inflammation; in blood sample taken from the forearm antecubital vein

    Time frame: At three time points before and four time points after 20 minutes of exercise or seated rest (In total over 2 hours)

  10. Tumor necrosis factor alpha (TNF-α)

    as a measure of systemic inflammation; in blood sample taken from the forearm antecubital vein

    Time frame: At three time points before and four time points after 20 minutes of exercise or seated rest (In total over 2 hours)

  11. Mood

    measured with a short version of Positive and Negative Affect Schedule (PANAS-SF) that include 5 positive and 5 negative affect states; the scoring scale is from 1 (very slightly or not at all) to 5 (extremely)

    Time frame: At two time points before and two time points after 20 minutes of exercise or seated rest (In total over 2 hours)

  12. Mental fatigue

    measured using Visual Analogue Scale (VAS-F); scoring scale: a line with 100 mm in length with scores falling between 0 mm (extremely alert) and 100 mm (extremely tired)

    Time frame: At two time points before and two time points after 20 minutes of exercise or seated rest (In total over 2 hours)

  13. Physical fatigue

    measured using Borg Rating of Perceived Exertion scale; scoring scale: from 6 (no exertion) to 20 (maximal exertion)

    Time frame: At two time points before and two time points after 20 minutes of exercise or seated rest (In total over 2 hours)

  14. Sleep quality

    measured using a Single-Item Sleep Quality Scale; scoring scale is from 0 (terrible) to 10 (excellent)

    Time frame: Over the night before and the night after each experimental session (In total over 36 hours)

  15. Sleepiness

    measured using Karolinska Sleepiness Scale; scoring scale is from 1 (extremely alert) to 9 (extremely sleepy)

    Time frame: At single time point before 20 minutes of exercise or seated rest

  16. Heart rate variability

    as an additional indicator of stress-related symptoms; measured with heart rate sensor and monitor

    Time frame: Over the night before and the night after each experimental session (In total over 36 hours)

  17. Augmentation index

    as a measure of arterial stiffness and indicator of cardiovascular health

    Time frame: At a single time point at baseline

07

Study locations

1 site
  • The Swedish School of Sport and Health Sciences
    Stockholm, 11433, Sweden
08

References and documents

Individual participant data

Plan to share: No — There is no current plan to make individual participant data available to other researchers.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Oct 2025, 19 months.

Of 35 interventional studies with no phase under Neuroinflammatory Diseases, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 44. This study's 19 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2024
First posted
Feb 7, 2024
StartActual
Feb 15, 2024
Primary completionActual
Oct 6, 2025
CompletionActual
Oct 21, 2025
Last update
Dec 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06245538
Lead sponsor
The Swedish School of Sport and Health Sciences
Collaborators
The Knowledge Foundation, Avonova, SATS, Itrim
Responsible party
Maria Ekblom (Professor, The Swedish School of Sport and Health Sciences) — Principal investigator
First posted
Feb 7, 2024
Start date
Feb 15, 2024
Primary completion
Oct 6, 2025
Completion
Oct 21, 2025
Last update
Dec 2, 2025

Study contacts

Maria Ekblom, PhD
principal investigator · The Swedish School of Sport and Health Sciences (GIH)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion